Atlas One · Host Biology · Scale 07 — System

IDH-Mutant Glioma

IDH-mutant glioma (Grade 2-3) defined by IDH1/2 mutations; 2-HG → TET2 inhibition → G-CIMP hypermethylation; WHO 2021 separates astrocytoma (ATRX LOF) from oligodendroglioma (1p/19q codeletion); vorasidenib FDA-approved August 2024 (INDIGO trial); median OS ~10-15 years.

Also known as: IDH-mutant glioma, IDH glioma, IDH mutant astrocytoma, IDH mutant oligodendroglioma, lower grade glioma, LGG, diffuse glioma IDH, IDH1 glioma, IDH1 R132H glioma, Grade 2 glioma vorasidenib

Scale 07 — SystemScale
draftStatus
2026-06-07Last Reviewed
This is an auto-generated stub page built from atlas entry frontmatter. A richer hand-crafted page is planned. See the atlas source for the full entry including detailed body sections.
idh-mutant-glioma

IDH-Mutant Glioma

IDH-mutant glioma (Grade 2-3) defined by IDH1/2 mutations; 2-HG → TET2 inhibition → G-CIMP hypermethylation; WHO 2021 separates astrocytoma (ATRX LOF) from oligodendroglioma (1p/19q codeletion); vorasidenib FDA-approved August 2024 (INDIGO trial); median OS ~10-15 years.

Entry Metadata

FieldValue
IDidh-mutant-glioma
NameIDH-Mutant Glioma
Statusdraft
Last reviewed2026-06-07
Atlas01-human
Scale07-system

Cross-Atlas Connections

connects-toAtrx connects-toIdh1 connects-toTet2 connects-toCdkn2A connects-toBrain connects-toGlioblastoma connects-toAstrocyte connects-toMedulloblastoma connects-toAml connects-toCholangiocarcinoma

Sources